Shengjin Yu, Huiming Lv, Jinhui Zhang, He Zhang, Weiwei Ju, Yu Jiang*, Lijuan Lin*
Oncologie, Vol.24, No.3, pp. 539-551, 2022, DOI:10.32604/oncologie.2022.024882
- 19 September 2022
Abstract Background: Although heparanase/syndecan-1 axis is involved in malignant progression of many cancers, its
significance in liver cancer is not well understood. In this study, we explored the value of heparanase/syndecan-1 axis
expression in liver cancer and the intervention mechanisms that target this axis by inhibiting the proliferation of
hepatocellular carcinoma cells. Materials and Methods: We conducted tissue microarray analysis that included
90 primary liver cancer and their corresponding adjacent samples to evaluate the expression of heparanase and syndecan-1 and their correlation with clinicopathologic characteristics. RNA interference and western blot assays were
performed to analyze the effect of… More >